The antitumor effects of OTX015, a new pan BET inhibitor used in 1/2 phase clinical trials in different malignancies, have been assessed in ovarian cancer (OC) in vitro models, SKOV3 cells, representing an adenocarcinoma OC tumor, and UWB1.289 cells, deriving from a papillary serous histology OC tumor. This evidence concerns the gene DNER and ovarian carcinoma.